Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease

NCT: NCT07572071 · RECRUITING

NCT IDNCT07572071
StatusRECRUITING
Start Date2025-08-01
Completion2030-08-01

Brief Summary

Dopason is a phase I, open-label, multicenter, single-arm clinical trial designed to evaluate the safety and feasibility of intraputaminal transplantation of human embryonic stem cell-derived dopaminergic progenitor cells (DopaCells) in patients with moderately severe Parkinson's disease.

Frequently Asked Questions

What is Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease?

Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease is a clinical trial registered under NCT07572071. Current status: RECRUITING.

What is the status of NCT07572071?

The current status of NCT07572071 (Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease) is: RECRUITING.

When did Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease start?

Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease started on 2025-08-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑